Hyaluron Contract Manufacturing HCM Announces Patent Approval: related news

Hyaluron Contract Manufacturing (HCM) Announces Patent Approval

PRNewswire/ -- Hyaluron, Inc. dba Hyaluron Contract Manufacturing (HCM) is pleased to announce the grant of a patent and the registration of a trademark for its proprietary process for aseptic online vacuum filling and online vacuum stoppering of low viscosity liquids in syringes. BUBBLE-FREE FILLING(R) enhances product stability for oxygen sensitive compounds where dissolved oxygen negatively impacts solution stability. BUBBLE-FREE FILLING(R) also provides additional assurances of sterility by reducing stopper movement as well as creating an unfavorable environment for the growth of aerobic micro-organisms.

Hyaluron Contract Manufacturing (HCM) Announces Patent Approval

BURLINGTON, Mass., June 24, 2008 /PRNewswire/ -- Hyaluron, Inc. dba Hyaluron Contract Manufacturing (HCM) is pleased to announce the grant of a patent and the registration of a trademark for its proprietary process for aseptic online vacuum filling and online vacuum stoppering of low viscosity liquids in syringes. BUBBLE-FREE FILLING(R) enhances product stability for oxygen sensitive compounds where dissolved oxygen negatively impacts solution stability. BUBBLE-FREE FILLING(R) also provides additional assurances of sterility by reducing stopper movement as well as creating an unfavorable environment for the growth of aerobic micro-organisms.

EntreMed receives new patent for 2-Methoxyestradiol analogs

Add our medical news to digg - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to NewsVine - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Fark - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Furl - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Shadows - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to YahooMyWeb - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Reddit -EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to StumbleUpon - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Facebook - EntreMed receives new patent for 2-Methoxyestradiol analogs

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling...

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill) CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware.

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

Santarus Announces Issuance Date of Additional U.S. Patent

Santarus, Inc. SNTS, a specialty pharmaceutical company, today announced that its licensor, the University of Missouri, has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent application number 10/641,732 will issue on July 15, 2008 as U.S. patent number 7,399,772. The new patent has claims covering methods for treating acid-caused gastrointestinal disorders by administering a solid pharmaceutical composition comprising non-enteric coated omeprazole and certain antacids. A Notice of Allowance was sent by the USPTO in April 2008. The new patent will have a July 2016 expiration date.

Santarus Announces Issuance Date of Additional U.S. Patent Covering Zegerid Products

SAN DIEGO--(BUSINESS WIRE)--Jul 8, 2008 - Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that its licensor, the University of Missouri, has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent application number 10/641,732 will issue on July 15, 2008 as U.S. patent number 7,399,772. The new patent has claims covering methods for treating acid-caused gastrointestinal disorders by administering a solid pharmaceutical composition comprising non-enteric coated omeprazole and certain antacids. A Notice of Allowance was sent by the USPTO in April 2008. The new patent will have a July 2016 expiration date.

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

PATENT REFORM IS NOT NECESSARY

Virtually all of the problems of the U.S. Patent system, including the high cost of obtaining a patent can be attributed to examiners issuing improper "bogus" rejections. While I know this is tue from my experience as a patent examiner, I performed a survey {using the PTO's Patent Application Information Retrieval (PAIR) system} of the 50 most recently issued patents classified in Class 435, Chemistry: Molecular Biology and Microbiology. In 76% of these patents, the examiner indicated in the first Office action that there was no allowable subject matter, i.e. none of the claims are patentable. Are the abilities of patent attorneys so low that over 75% of patent applications as filed do not contain at least one allowable claim? Or are the examiners writing "bogus" rejections? The answer is the latter.

Unidym Inc. Announces Launch of Patent License Option Program and Execution of First Patent License Option

Unidym Inc. Announces Launch of Patent License Option Program and Execution of First Patent License Option

Techalt, Inc. Announces U.S. Patent Office Grants Petition to Revive Review of the Patent Application for Stan's Rodeo Ointment (''SRO'')

Techalt, Inc. Announces U.S. Patent Office Grants Petition to Revive Review of the Patent Application for Stan's Rodeo Ointment (''SRO'')

Dynamic Biometric Systems Announces That the US Patent Office Has Approved Claims 1 Through 15 of Patent #1; Receives an Order for 1,000 Bio-Pens and FINRA Has Approved Trading Status

Dynamic Biometric Systems Announces That the US Patent Office Has Approved Claims 1 Through 15 of Patent #1; Receives an Order for 1,000 Bio-Pens and FINRA Has Approved Trading Status

Non-Disruptive Backups and Migrations Enhances European Patent Protection and Management

The European Patent Office grants European patents. The EPO carries out searches and substantive examinations on a steadily rising number of European patent applications and international applications filed under the Patent Cooperation Treaty. The European Patent Office (EPO) needed to support up to 60 million patents documents and 800,000 patents within a high availability and ultra resilient DB2 environment. The European Patent Office deployed BMC DB2 solutions to more effectively support its customers and the management of its patent applications.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,” said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

Search took 0.34 seconds.